Pfizer And Medivation Agreement To Co-Develop And Market Dimebon For Alzheimer’s And Huntington’s Diseases Treatment

Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation’s investigational drug for treatment of Alzheimer’s disease and Huntington’s disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer’s disease (http://www.connectionstudy.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on September 8th, 2008